{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 33,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a vertical process flow to demonstrate clinical progression and de-risking.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/10",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.45,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "In Vitro, In Vivo, Predictive Dose Modeling, Phase 1, CSF Concentration, Phase 1b Cognitive Challenge, Phase 2A, DPNP, Phase 2a, CIAS",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0b4b68a-bb30-4b9b-83a6-9dc29932c04d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.2,
        "x": 0.75,
        "y": 0.2
      },
      "kind": "list",
      "text": "Consistent PK-PD relationship, Confidence in active dose range, Complete CMC package, Excellent tolerability and safety, Multiple clinical cognitive signals, De-risked path forward",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f583736b-30b8-4844-9cc2-6c2841b167f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "RL-007: demonstrated pro-cognitive treatment for CIAS. 1. Pharma developed product in-licensed with extensive pre-clinical & clinical data package. 2. Human Phase 1 + 2 data show replicated, clinically significant learning and memory effects, consistent with broad pre-clinical pro-cognitive data. 3. Well tolerated (>500 subjects dosed), centrally acting oral drug. 4. Initial indication: cognitive impairment associated with schizophrenia (CIAS) is characterized by episodic learning & memory deficits - no approved treatment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f53c76fd-e2d4-4ef0-985e-a29525e60cea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: CSF = Cerebrospinal Fluid, DPNP = Diabetic Peripheral Neuropathic Pain, PK = Pharmacokinetics, PD = Pharmacodynamics, CNS = Central Nervous System, CMC = Chemistry, Manufacturing, and Controls",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7d83e29-02b4-41dc-9377-b40fd15762ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "RL-007: a de-risked pro-cognitive neuromodulator investigated in >500 subjects with excellent tolerability in humans",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4075aae5-9456-4363-8520-6e40ba097508",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "bb5f462c-8613-4186-bb4e-91594cce02ea",
      "evidence": "Vertical progression of clinical trial phases",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "c03b4929-2253-4e87-9891-73e59cfb766a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck showcases traction for various programs, including RL-007, COMP360, and GRX-917, demonstrating progress and potential for growth.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}